Gilead Sciences Inc.
Gilead Sciences Approves Amendments and Director Elections at 2024 Annual Meeting
Summary
At Gilead Sciences, Inc.'s 2024 Annual Meeting on May 8, 2024, stockholders approved several significant amendments to the Company's governance, including the adoption of new Delaware law provisions regarding officer exculpation. The Board of Directors also elected nine new directors. Additionally, stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, and approved the compensation of the Company's Named Executive Officers on an advisory basis. Several stockholder proposals, including those requesting Board member representation from non-management employees and reports on risks related to state policies on abortion, were not approved by the stockholders.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement